Conference call and webcast to be held at
4:30 p.m. EDT
NEW
HAVEN, Conn., Nov. 1, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for difficult
to treat patients with chronic cough in idiopathic pulmonary
fibrosis (IPF), refractory chronic cough, and prurigo
nodularis, today announced that senior management will host a
conference call and live audio webcast on Thursday, November
9, 2023, at 4:30 p.m. ET, to provide a corporate update and
review the Company's financial results for the third quarter ended
September 30, 2023.
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 5615817. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics, Inc.
Trevi
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing the investigational therapy Haduvio™ (oral nalbuphine
ER) for difficult to treat patients with chronic cough in
idiopathic pulmonary fibrosis (IPF), refractory chronic cough, and
prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and
µ-opioid receptor antagonist that works both centrally as well as
peripherally in the lungs and has the potential for a synergistic
anti-tussive effect to treat chronic cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. There are no approved therapies for the treatment of chronic
cough in IPF and current treatment options provide minimal relief
to patients. In IPF, chronic cough may lead to worsening disease
and may be associated with a higher risk of progression, death, or
need for lung transplant.
Parenteral nalbuphine is not scheduled by the U.S. Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information,
visit www.TreviTherapeutics.com and follow Trevi
on Twitter and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q3-2023-financial-results-and-provide-a-corporate-update-on-november-9-2023-301974717.html
SOURCE Trevi Therapeutics, Inc.